JP2021510380A - 放射線感受性組織における細胞保護薬の選択的堆積およびその使用 - Google Patents

放射線感受性組織における細胞保護薬の選択的堆積およびその使用 Download PDF

Info

Publication number
JP2021510380A
JP2021510380A JP2020546284A JP2020546284A JP2021510380A JP 2021510380 A JP2021510380 A JP 2021510380A JP 2020546284 A JP2020546284 A JP 2020546284A JP 2020546284 A JP2020546284 A JP 2020546284A JP 2021510380 A JP2021510380 A JP 2021510380A
Authority
JP
Japan
Prior art keywords
radiation
tissue
dose
organ
organs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020546284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510380A5 (https=
Inventor
ツアー ジェイムズ
ツアー ジェイムズ
タニグチ カレン
タニグチ カレン
メースン キャシー
メースン キャシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William Marsh Rice University
Original Assignee
William Marsh Rice University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Marsh Rice University filed Critical William Marsh Rice University
Publication of JP2021510380A publication Critical patent/JP2021510380A/ja
Publication of JP2021510380A5 publication Critical patent/JP2021510380A5/ja
Priority to JP2023204518A priority Critical patent/JP2024026262A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1094—Shielding, protecting against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020546284A 2017-11-21 2018-11-19 放射線感受性組織における細胞保護薬の選択的堆積およびその使用 Pending JP2021510380A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023204518A JP2024026262A (ja) 2017-11-21 2023-12-04 放射線感受性組織における細胞保護薬の選択的堆積およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589155P 2017-11-21 2017-11-21
US62/589,155 2017-11-21
PCT/US2018/061888 WO2019103983A1 (en) 2017-11-21 2018-11-19 Selective accretion of cytoprotectant in radiation-sensitive tissues and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023204518A Division JP2024026262A (ja) 2017-11-21 2023-12-04 放射線感受性組織における細胞保護薬の選択的堆積およびその使用

Publications (2)

Publication Number Publication Date
JP2021510380A true JP2021510380A (ja) 2021-04-22
JP2021510380A5 JP2021510380A5 (https=) 2022-01-04

Family

ID=66631627

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546284A Pending JP2021510380A (ja) 2017-11-21 2018-11-19 放射線感受性組織における細胞保護薬の選択的堆積およびその使用
JP2023204518A Pending JP2024026262A (ja) 2017-11-21 2023-12-04 放射線感受性組織における細胞保護薬の選択的堆積およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023204518A Pending JP2024026262A (ja) 2017-11-21 2023-12-04 放射線感受性組織における細胞保護薬の選択的堆積およびその使用

Country Status (8)

Country Link
US (1) US11478489B2 (https=)
EP (1) EP3713534A4 (https=)
JP (2) JP2021510380A (https=)
KR (1) KR20200121286A (https=)
CN (1) CN111867599A (https=)
AU (2) AU2018372917A1 (https=)
CA (1) CA3083238C (https=)
WO (1) WO2019103983A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855445B2 (en) 2016-04-01 2018-01-02 Varian Medical Systems, Inc. Radiation therapy systems and methods for delivering doses to a target volume
US10092774B1 (en) 2017-07-21 2018-10-09 Varian Medical Systems International, AG Dose aspects of radiation therapy planning and treatment
US11712579B2 (en) 2017-07-21 2023-08-01 Varian Medical Systems, Inc. Range compensators for radiation therapy
US11590364B2 (en) 2017-07-21 2023-02-28 Varian Medical Systems International Ag Material inserts for radiation therapy
US10549117B2 (en) 2017-07-21 2020-02-04 Varian Medical Systems, Inc Geometric aspects of radiation therapy planning and treatment
US10843011B2 (en) 2017-07-21 2020-11-24 Varian Medical Systems, Inc. Particle beam gun control systems and methods
US10183179B1 (en) 2017-07-21 2019-01-22 Varian Medical Systems, Inc. Triggered treatment systems and methods
EP3654976A1 (en) 2017-07-21 2020-05-27 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
US11007381B2 (en) 2017-11-16 2021-05-18 Varian Medical Systems, Inc Increased beam output and dynamic field shaping for radiotherapy system
US10910188B2 (en) 2018-07-25 2021-02-02 Varian Medical Systems, Inc. Radiation anode target systems and methods
US10814144B2 (en) 2019-03-06 2020-10-27 Varian Medical Systems, Inc. Radiation treatment based on dose rate
US11116995B2 (en) 2019-03-06 2021-09-14 Varian Medical Systems, Inc. Radiation treatment planning based on dose rate
US11103727B2 (en) 2019-03-08 2021-08-31 Varian Medical Systems International Ag Model based PBS optimization for flash therapy treatment planning and oncology information system
US11090508B2 (en) 2019-03-08 2021-08-17 Varian Medical Systems Particle Therapy Gmbh & Co. Kg System and method for biological treatment planning and decision support
US10918886B2 (en) 2019-06-10 2021-02-16 Varian Medical Systems, Inc. Flash therapy treatment planning and oncology information system having dose rate prescription and dose rate mapping
US11291859B2 (en) 2019-10-03 2022-04-05 Varian Medical Systems, Inc. Radiation treatment planning for delivering high dose rates to spots in a target
US12390662B2 (en) 2020-04-02 2025-08-19 Siemens Healthineers International Ag System and method for proton therapy treatment planning with proton energy and spot optimization
US11865361B2 (en) 2020-04-03 2024-01-09 Varian Medical Systems, Inc. System and method for scanning pattern optimization for flash therapy treatment planning
US11541252B2 (en) 2020-06-23 2023-01-03 Varian Medical Systems, Inc. Defining dose rate for pencil beam scanning
US11957934B2 (en) 2020-07-01 2024-04-16 Siemens Healthineers International Ag Methods and systems using modeling of crystalline materials for spot placement for radiation therapy
US12064645B2 (en) 2020-07-02 2024-08-20 Siemens Healthineers International Ag Methods and systems used for planning radiation treatment
CN113768940A (zh) * 2021-08-25 2021-12-10 中国辐射防护研究院 一种放射性肺损伤的防护方法
WO2025075691A1 (en) * 2023-10-07 2025-04-10 Xerient Pharma Ltd. Irradiation protection methods uses and compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102210694A (zh) * 2011-04-12 2011-10-12 上海长征医院 一种氨磷汀口服制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573253B2 (en) * 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
WO2007047315A1 (en) 2005-10-20 2007-04-26 Albemarle Corporation Amifostine dihydrate crystalline composition
US9393439B2 (en) 2010-03-01 2016-07-19 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
US9408882B2 (en) 2011-03-18 2016-08-09 Albert Einstein College Of Medicine, Inc. Oral administration of melanin for protection against radiation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102210694A (zh) * 2011-04-12 2011-10-12 上海长征医院 一种氨磷汀口服制剂及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
INT. J. RADIAT. BIOL., vol. 52, no. 1, JPN6022053270, 1987, pages 21 - 29, ISSN: 0005121016 *
INT. J. RADIAT. BIOL., vol. 81, no. 3, JPN6022053272, 2005, pages 251 - 257, ISSN: 0005121014 *
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 453, JPN6022053271, 2013, pages 441 - 447, ISSN: 0005121013 *
JPP, vol. 56, JPN6022053273, 2004, pages 1119 - 1125, ISSN: 0005121015 *

Also Published As

Publication number Publication date
AU2024227095A1 (en) 2024-10-24
WO2019103983A1 (en) 2019-05-31
CA3083238A1 (en) 2019-05-31
EP3713534A1 (en) 2020-09-30
EP3713534A4 (en) 2021-08-25
AU2018372917A1 (en) 2020-06-18
JP2024026262A (ja) 2024-02-28
KR20200121286A (ko) 2020-10-23
US11478489B2 (en) 2022-10-25
US20200360406A1 (en) 2020-11-19
CN111867599A (zh) 2020-10-30
CA3083238C (en) 2024-02-13

Similar Documents

Publication Publication Date Title
JP2021510380A (ja) 放射線感受性組織における細胞保護薬の選択的堆積およびその使用
US10238630B2 (en) Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
EP3038600B1 (en) Nanoparticle drug delivery system and method of treating cancer and neurotrauma
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
ES2881928T3 (es) Profármacos de etopósido para su uso en el direccionamiento a las células madre cancerosas
Li et al. Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed via the ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: a prospective phase I study
US20100203110A1 (en) Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production
WO2019094053A1 (en) Disulfiram and copper salt dosing regimen
CN102056609B (zh) 药物组合
US10617672B2 (en) Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C
CN119345359A (zh) 用于膀胱癌的新辅助疗法
JP7529305B2 (ja) アスタチン溶液及びその製造方法
JP2002515439A (ja) 脳腫瘍の治療のためのエーデルホシン
EP4230205B1 (en) Polyethylene glycol-modified irinotecan and temozolomide compositions
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
JP2002540172A (ja) 腫瘍治療の増強のためのスフィンゴミエリン含有調製物
ES3017257T3 (en) Abt-751 and ionizing radiation for use in treating a brain tumor
WO2026065490A1 (zh) Mitoxantrone在制备药物中的用途、治疗或预防神经内分泌肿瘤的方法
이윤택 Pharmacokinetic distribution of paclitaxel, albumin-binding paclitaxel, and liposomal-encapsulated albumin-binding paclitaxel upon gastric subserosal administration in rat and rabbit model
US12319915B2 (en) Cytotoxic fluoropyrimidine polymers and methods of use thereof
WO2025188928A1 (en) Administration of low-dose thiostrepton for treating cancer
WO2021102142A1 (en) Okn-007 as a therapeutic agent
BR122024017509B1 (pt) Composições lipossomais de antifolatos poliglutamatados dglutamil, seu uso e método de preparação
HK1152640B (en) Pharmaceutical combination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230802